array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Tekla Life Sciences Investors" ["slug"]=> string(38) "30be8-us-tekla-life-sciences-investors" ["logo"]=> NULL ["description"]=> string(523) "Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund that primarily invests in the life sciences industry. The fund aims to provide long-term capital appreciation through investments in companies in the life sciences industry with potential for above-average long-term growth. It focuses on smaller, emerging companies and may invest up to 40% of its assets in restricted securities of both public and private companies. The fund is traded on the New York Stock Exchange under the ticker HQL." ["address_street"]=> string(17) "2 Liberty Sq FL 9" ["address_place"]=> string(6) "Boston" ["address_region"]=> string(13) "Massachusetts" ["founding_date"]=> string(10) "2000-01-26" ["website_domain"]=> string(12) "teklacap.com" ["website_url"]=> string(24) "https://www.teklacap.com" ["industry_codes"]=> array(1) { [0]=> string(39) "Management Investment Offices, Open-End" } ["employee_count"]=> int(7) ["article_count"]=> int(78) } ["articles"]=> array(2) { [0]=> array(7) { ["title_en"]=> string(70) "Tekla Funds Approve New Investment Advisory Agreements With abrdn Inc." ["snippet_en"]=> string(190) "Tekla Capital Management LLC announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its four closed-end funds." ["url"]=> string(118) "https://www.nasdaq.com/press-release/tekla-funds-approve-new-investment-advisory-agreements-with-abrdn-inc.-2023-10-27" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-06-30" ["categories"]=> array(5) { [0]=> string(25) "Business Model Resilience" [1]=> string(18) "General Investment" [2]=> string(15) "Deals & Tenders" [3]=> string(13) "Collaboration" [4]=> string(19) "Investment Requests" } } [1]=> array(7) { ["title_en"]=> string(59) "Tekla Capital Management LLC Announces Proposed Transaction" ["snippet_en"]=> string(290) "BOSTON, June 20, 2023--Tekla Capital Management LLC (Tekla) announced today that it has entered into an agreement with abrdn Inc. for a strategic transaction involving four NYSE-listed healthcare & biotech thematic closed-end funds (the Funds), totaling $3.1 bn in assets under management.1" ["url"]=> string(84) "https://finance.yahoo.com/news/tekla-capital-management-llc-announces-214800997.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/27f9210f-e79b-418d-a9ec-eb1db0a63f25" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-06-20" ["categories"]=> array(2) { [0]=> string(15) "Deals & Tenders" [1]=> string(13) "Collaboration" } } } ["category_annotations"]=> array(22) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(16) } [1]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(6) } [2]=> array(2) { ["name"]=> string(10) "Tax Havens" ["count"]=> int(6) } [3]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(5) } [4]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(4) } [5]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(4) } [6]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(4) } [7]=> array(2) { ["name"]=> string(16) "Share Repurchase" ["count"]=> int(4) } [8]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(3) } [9]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(2) } [10]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [11]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(2) } [12]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(2) } [13]=> array(2) { ["name"]=> string(22) "Business Restructuring" ["count"]=> int(2) } [14]=> array(2) { ["name"]=> string(20) "Corporate Governance" ["count"]=> int(2) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(23) "Supply Chain Management" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(19) "Investment Requests" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(20) "Business Development" ["count"]=> int(1) } } } 30be8-us-tekla-life-sciences-investors